安罗替尼联合盐酸埃克替尼治疗晚期非小细胞肺癌合并脑转移的疗效与安全性分析  

Efficacy and Safety Analysis of Anlotinib Combined with Erlotinib in Treating Advanced Non-Small Cell Lung Cancer with Brain Metastasis

作　　者：侯士于 樊涛[1] 徐瑞凤[1] HOU Shiyu;FAN Tao;XU Ruifeng(Department of Radiotherapy,The First Affiliated Hospital of Nanyang Medical College,Nanyang Henan 473000,China)

机构地区：[1]南阳医学高等专科学校第一附属医院放疗科,河南南阳473000

出　　处：《临床研究》2025年第2期34-37,共4页Clinical Research

摘　　要：目的本项研究着重于分析安罗替尼联用盐酸埃克替尼在治疗晚期非小细胞肺癌患者并发脑转移过程中的疗效及其安全性。方法选取2021年1月至2023年9月在南阳医学高等专科学校第一附属医院接受治疗的88例存在表皮生长因子受体(EGFR)基因突变阳性的晚期非小细胞肺癌并发脑转移患者的临床资料进行回顾性研究。依照患者所采用的治疗策略差异,将这些患者划分为对照组与观察组,各44例。对照组仅使用盐酸埃克替尼单一药物治疗,而观察组在盐酸埃克替尼治疗的基础上增加安罗替尼胶囊联合用药。比较两组患者近期病情总体反应、脑部转移灶近期疗效、长期疗效以及治疗期间不良事件的发生情况。结果在两组患者整体病情近期疗效的对比中,观察组患者的客观缓解率、疾病控制率均显著高于对照组,差异均有统计学意义(P<0.05)。观察组患者的无进展生存时间中位数为10.0个月,95%CI为(8.522~11.478)个月。对照组患者的无进展生存时间中位数为6.0个月,95%CI为(5.072~6.928)个月。两组的数据差异具有统计学意义(Log-rankχ^(2)=10.485,P<0.05)。两组受试者在接受治疗期间所遭遇的所有不良症状均属于轻度至中度,未观察到重度反应。在观察组中,有四位受试者因出现不良症状而对安罗替尼的用药剂量进行了调整。所有受试者均未出现停止用药的情况,亦无与用药直接相关的死亡案例。观察组受试者出现咯血、口腔黏膜损伤及高血压的情况明显多于对照组,差异均有统计学意义(P<0.05)。两组受试者其余不良症状发生率比较,差异无统计学意义(P>0.05)。结论采用安罗替尼搭配盐酸埃克替尼作为治疗方案,对于EGFR变异阳性的非小细胞肺癌且同时伴有脑部转移情况的患者,展现出积极的治疗成效。该方案有助于提升患者的客观缓解率及对疾病的控制能力,有效延长了患者无疾病进Objective This study focuses on analyzing the efficacy and safety of Anlotinib combined with Erlotinib in treating patients with advanced non-small cell lung cancer with concomitant brain metastasis.Methods A retrospective study was conducted using clinical data from 88 patients with epidermal growth factor receptor(EGFR)gene mutation-positive advanced non-small cell lung cancer with brain metastasis,who were treated at The First Affiliated Hospital of Nanyang Medical College from January 2021 to September 2023.Based on the treatment strategies used,these patients were divided into a control group and an observation group,with 44 patients in each group.The control group received treatment with Erlotinib alone,whereas the observation group received Anlotinib capsules in addition to Erlotinib.The overall response to treatment,efficacy on brain metastatic lesions,long-term efficacy,and the occurrence of adverse events during treatment were compared between the two groups.Results In terms of overall disease response,the observation group showed significantly higher objective response rates and disease control rates compared to the control group,with statistically significant differences(P<0.05).The median progression-free survival in the observation group was 10.0 months(95%CI:8.522~11.478 months),while the median Progression-free survival in the control group was 6.0 months(95%CI:5.072~6.928 months).The data difference between the two groups was statistically significant(Log-rankχ^(2)=10.485,P<0.05).All adverse symptoms encountered by patients during treatment in both groups were of mild to moderate severity,with no severe reactions observed.In the observation group,four patients had their Anlotinib dosage adjusted due to adverse symptoms.None of the subjects discontinued medication,and there were no drug-related deaths.The incidence of hemoptysis,oral mucosal damage,and hypertension was significantly higher in the observation group compared to the control group,with statistically significant differences(P<0.05).Th

关 键 词：安罗替尼 埃克替尼 非小细胞肺癌 脑转移 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]